Apoptosis Repressor With Caspase Recruitment Domain Is Required for Cardioprotection in Response to Biomechanical and Ischemic Stress

Background— Ischemic heart disease and heart failure are associated with an increased loss of cardiomyocytes due to apoptosis. Whether cardiomyocyte apoptosis plays a causal role in the pathogenesis of heart failure remains enigmatic. The apoptosis repressor with caspase recruitment domain (ARC) is a recently discovered antiapoptotic factor with a highly specific expression pattern in striated muscle and neurons. ARC is a master regulator of cardiac death signaling because it is the only known factor that specifically inhibits both the intrinsic and extrinsic apoptotic death pathway. In this study we attempted to elucidate the physiological role of ARC and to understand pathophysiological consequences resulting from its deletion. Methods and Results— We generated ARC-deficient mice, which developed normally to adulthood and had no abnormality in cardiac morphology and function under resting conditions. On biomechanical stress induced by aortic banding, ARC-deficient mice developed accelerated cardiomyopathy compared with littermate controls, which was characterized by reduced contractile function, cardiac enlargement, and myocardial fibrosis. Likewise, ischemia/reperfusion injury of ARC-deficient mice resulted in markedly increased myocardial infarct sizes. Although in both instances a significant increase in apoptotic cardiomyocytes could be observed in ARC-deficient mice, neither in vitro nor in vivo studies revealed any effect of ARC on classic hypertrophic cardiomyocyte growth responses. The pathophysiological relevance of downregulated ARC levels was underscored by specimens from failing human hearts showing markedly reduced ARC protein levels. Conclusions— Our study identifies a tissue-specific antiapoptotic factor that is downregulated in human failing myocardium and that is required for cardioprotection in pressure overload and ischemia.

[1]  Michael D Schneider,et al.  Learning from failure: congestive heart failure in the postgenomic age. , 2005, The Journal of clinical investigation.

[2]  J. Ross,et al.  Small proline‐rich protein 1A is a gp130 pathway‐ and stress‐inducible cardioprotective protein , 2004, The EMBO journal.

[3]  S. Akira,et al.  Pressure Overload Induces Cardiac Dysfunction and Dilation in Signal Transducer and Activator of Transcription 6-Deficient Mice , 2004, Circulation.

[4]  S. Korsmeyer,et al.  Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. , 2004, Molecular cell.

[5]  Michael D. Schneider,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury , 2004, Circulation research.

[6]  M. Crow,et al.  Apoptosis Repressor with Caspase Recruitment Domain Protects against Cell Death by Interfering with Bax Activation* , 2004, Journal of Biological Chemistry.

[7]  P. Poole‐Wilson,et al.  Regenerative capacity of the myocardium: implications for treatment of heart failure , 2004, The Lancet.

[8]  G. Dorn,et al.  Phenotyping hypertrophy: eschew obfuscation. , 2003, Circulation research.

[9]  T. Gardner,et al.  Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. , 2003, The Journal of thoracic and cardiovascular surgery.

[10]  N. Maulik,et al.  Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. , 2003, American journal of physiology. Heart and circulatory physiology.

[11]  R. Kitsis,et al.  A mechanistic role for cardiac myocyte apoptosis in heart failure. , 2003, The Journal of clinical investigation.

[12]  S. Vatner,et al.  Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. , 2003, The Journal of clinical investigation.

[13]  J. Schaper,et al.  Myocytes Die by Multiple Mechanisms in Failing Human Hearts , 2003, Circulation research.

[14]  P. Anversa,et al.  Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. , 2003, Circulation research.

[15]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[16]  Martin Ungerer,et al.  Essential myosin light chain as a target for caspase-3 in failing myocardium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Crow,et al.  TAT Protein Transduction Into Isolated Perfused Hearts: TAT–Apoptosis Repressor With Caspase Recruitment Domain Is Cardioprotective , 2002, Circulation.

[18]  R. Dietz,et al.  Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC. , 2002, Molecular cell.

[19]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes , 2001, Nature Medicine.

[20]  Stephanie Birkey Reffey,et al.  Characterization of XIAP-Deficient Mice , 2001, Molecular and Cellular Biology.

[21]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. , 2001, Nature medicine.

[22]  K. Chien,et al.  Stress Pathways and Heart Failure , 1999, Cell.

[23]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[24]  J. Ross,et al.  Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. , 1998, Journal of molecular and cellular cardiology.

[25]  John W. Adams,et al.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Chen,et al.  ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Anversa,et al.  Apoptosis and myocardial infarction , 1998, Basic Research in Cardiology.

[28]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[29]  P. Hornsby,et al.  Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis , 1996, The Journal of cell biology.

[30]  L. Gaboury,et al.  Apoptosis in pressure overload-induced heart hypertrophy in the rat. , 1996, The Journal of clinical investigation.

[31]  R. Kloner,et al.  Reperfusion injury induces apoptosis in rabbit cardiomyocytes. , 1994, The Journal of clinical investigation.

[32]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[33]  J. Ross,et al.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.